Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan

Olaolu Olayinka Oni; Oladapo Olayemi; Oluwasomidoyin Bello; Olubukola Adesina

doi:doi:10.11648/j.ijbecs.20220804.12

| Peer-Reviewed

Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan

Olaolu Olayinka Oni, Oladapo Olayemi, Oluwasomidoyin Bello, Olubukola Adesina

Published in International Journal of Biomedical Engineering and Clinical Science (Volume 8, Issue 4)

Received: 17 October 2022 Accepted: 7 November 2022 Published: 16 November 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Malaria in pregnancy is associated with many complications therefore the World Health Organization (WHO) in 2012 recommended monthly use of intermittent preventive therapy with sulphadoxine-pyrimethamine (IPTp-SP) to reduce the menace of this disease in malaria endemic region. This study assessed the fetomaternal outcomes of monthly doses of sulphadoxine-pyrimethamine as intermittent preventive treatment (IPTp-SP) in Ibadan. This study was a prospective cohort study. The fetomaternal outcomes of 200 consenting pregnant women on monthly IPTp-SP that completed the study at Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan were analysed. A proforma was used to collect data which included sociodemographic and obstetrics characteristics, prevalence of malaria among the participants and fetomaternal outcomes of the participants. Data obtained were subjected to analysis using statistical package for social sciences (SPSS) for window version 21 and results were presented in appropriate tables, charts and figures. Two hundred participants completed the study and although 11.7% of the participants had malaria parasitaemia at recruitment, only one participant had it at delivery. Most of the participants took 4 doses before delivery. Only 3% of the participants delivered at gestational age less than 34 weeks though 26.5% had preterm delivery. The mean PCV were 30.05±2.60 vs 32.63±3.40 at recruitment and delivery respectively. Only one out of 200 babies and two (1.0%) placental samples tested positive to malaria. The fetal and maternal outcomes of the participants were good following the use of monthly IPTp-SP therefore the uptake of monthly IPTp-SP should be encouraged among pregnant women in malaria endemic area.

Published in	International Journal of Biomedical Engineering and Clinical Science (Volume 8, Issue 4)
DOI	10.11648/j.ijbecs.20220804.12
Page(s)	48-52
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Malaria, Pregnant, Ibadan, Uptake, IPTp-SP, Fetal Outcomes, Maternal Outcomes

References

[1]	Dhiman, S., Yadav, K., Goswami, D., Das, N., Baruah, I., & Singh, L. (2012). Epidemiology and Risk Analysis of Malaria among Pregnant Women. Iran J Public Health. 41 (1): 1–8.
[2]	Dutta, D. (2008). Medical and surgical illness complicating pregnancy. Textbook of Obstetrics 5th ed.; 19: 296–299.
[3]	Opare-Addo, O. A. T. (2001). Malaria in Pregnancy. Comprehensive Obstetrics in the Tropics, 34, 250-260.
[4]	Brabin, B., Romagosa, C., Abdelgalil, S., Menéndez, C., Verhoeff, F., & McGready, R. et al. (2004). The sick placenta – The role of malaria. Placenta. 25: 359–378. doi.org/10.1016/j.placenta.2003.10.019
[5]	Tongo, O, Orimadegun, A., & Akinyinka, O. (2000). The use of intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnancy in Ibadan, Nigeria: Implications for policy. Journal of Public Health and Epid. 1 (1) 001-006.
[6]	McGready, R., Ashley, E., Nosten, F., & Rijken, M. (2010). Royal College of Obstetricians and Gynaecologists. The prevention of malaria in pregnancy, Green-top Guideline No. 54A.
[7]	WHO. Fact sheet: World Malaria Report 2015 and 2016 by WHO.
[8]	Salwa, D., & Hesham, M. (2016). Is Nigeria winning the battle against malaria? Prevalence risk factors and KAP assessment among Hausa communities in Kano State. Malar J, 15: 351.
[9]	Agboghoroma, C. (2014). Current management and prevention of malaria in pregnancy: a review. West Afr J Med. 33 (2): 91-9. PMID: 25236824.
[10]	WHO: Intermittent preventive treatment of malaria in pregnancy (IPTp) with Sulphadoxine- Pyrimethamine by WHO Evidence review group meeting report in Geneva 2012.
[11]	Federal Ministry of Health. National guidelines and strategies for malaria prevention and control during pregnancy. FMOH, Nigeria second Edn May, 2014.
[12]	National Malaria Elimination Program, ICF International. 2015 Nigeria Malaria Indicator Survey: Atlas of Key Indicators. Rockville, (MD): ICF International; 2016.
[13]	Francis, A., Ibrahim, H., Victor, A., Elizabeth, A., & Abraham, R. (2019). “Intermittent Preventive Treatment of Malaria in Pregnancy: Assessment of the Sulfadoxine-Pyrimethamine Three-Dose Policy on Birth Outcomes in Rural Northern Ghana,” Journal of Tropical Medicine, vol. 2019, Article ID 6712685, 10 pages, 2019.
[14]	Igboeli, N., Ukwe, C., & Aguwa, C., (2017). Effect of antimalarial prophylaxis with sulphadoxine-pyrimethamine on pregnancy outcomes in Nsukka, Nigeria. Malaria World Journal. 8: 3.
[15]	Mpogoro, F., Matovelo, D., Dosani, A., Ngallaba, S., Mugono, M., & Mazigo, H. (2014). Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district, North-Western Tanzania. Malar J 13, 455. doi.org/10.1186/1475-2875-13-455
[16]	Kayentao, K., Garner, P., van Eijk. A., Naidoo, I., Roper, C., & Mulokozi, A. et al. (2013). Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and Risks of low birth weight in African- Systematic review and Meta-analysis. JAMA, 309 (6): 594–604. doi: 10.1001/jama.2012.216231
[17]	Chico, R., Chaponda, E., Ariti, C., & Chandramohan, D. (2017). “Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infection,” Clinical Infectious Diseases, 64 (8): 1043-1051. doi: 10.1093/cid/cix026
[18]	Filler, S., Peter, K., Michael, T., Alan, M., Monica, E., & Robert, D. et al. (2006). Randomized trial of 2-dose versus monthly sulphadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infectious Diseases, 194 (3): 286-293. doi: 10.1086/505080.
[19]	Agomo, C., Oyibo, W., & Odukoya-Maije, F. (2011). Parasitologic Assessment of Two-Dose and Monthly Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTP-SP) in Lagos, Nigeria. Malaria research and treatment, 2011, 932895. doi.org/10.4061/2011/932895

Cite This Article

Plain Text BibTeX RIS

APA Style

Olaolu Olayinka Oni, Oladapo Olayemi, Oluwasomidoyin Bello, Olubukola Adesina. (2022). Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. International Journal of Biomedical Engineering and Clinical Science, 8(4), 48-52. https://doi.org/10.11648/j.ijbecs.20220804.12

Copy | Download

ACS Style

Olaolu Olayinka Oni; Oladapo Olayemi; Oluwasomidoyin Bello; Olubukola Adesina. Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. Int. J. Biomed. Eng. Clin. Sci. 2022, 8(4), 48-52. doi: 10.11648/j.ijbecs.20220804.12

Copy | Download

AMA Style

Olaolu Olayinka Oni, Oladapo Olayemi, Oluwasomidoyin Bello, Olubukola Adesina. Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. Int J Biomed Eng Clin Sci. 2022;8(4):48-52. doi: 10.11648/j.ijbecs.20220804.12

Copy | Download

@article{10.11648/j.ijbecs.20220804.12,
  author = {Olaolu Olayinka Oni and Oladapo Olayemi and Oluwasomidoyin Bello and Olubukola Adesina},
  title = {Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan},
  journal = {International Journal of Biomedical Engineering and Clinical Science},
  volume = {8},
  number = {4},
  pages = {48-52},
  doi = {10.11648/j.ijbecs.20220804.12},
  url = {https://doi.org/10.11648/j.ijbecs.20220804.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20220804.12},
  abstract = {Malaria in pregnancy is associated with many complications therefore the World Health Organization (WHO) in 2012 recommended monthly use of intermittent preventive therapy with sulphadoxine-pyrimethamine (IPTp-SP) to reduce the menace of this disease in malaria endemic region. This study assessed the fetomaternal outcomes of monthly doses of sulphadoxine-pyrimethamine as intermittent preventive treatment (IPTp-SP) in Ibadan. This study was a prospective cohort study. The fetomaternal outcomes of 200 consenting pregnant women on monthly IPTp-SP that completed the study at Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan were analysed. A proforma was used to collect data which included sociodemographic and obstetrics characteristics, prevalence of malaria among the participants and fetomaternal outcomes of the participants. Data obtained were subjected to analysis using statistical package for social sciences (SPSS) for window version 21 and results were presented in appropriate tables, charts and figures. Two hundred participants completed the study and although 11.7% of the participants had malaria parasitaemia at recruitment, only one participant had it at delivery. Most of the participants took 4 doses before delivery. Only 3% of the participants delivered at gestational age less than 34 weeks though 26.5% had preterm delivery. The mean PCV were 30.05±2.60 vs 32.63±3.40 at recruitment and delivery respectively. Only one out of 200 babies and two (1.0%) placental samples tested positive to malaria. The fetal and maternal outcomes of the participants were good following the use of monthly IPTp-SP therefore the uptake of monthly IPTp-SP should be encouraged among pregnant women in malaria endemic area.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan
AU  - Olaolu Olayinka Oni
AU  - Oladapo Olayemi
AU  - Oluwasomidoyin Bello
AU  - Olubukola Adesina
Y1  - 2022/11/16
PY  - 2022
N1  - https://doi.org/10.11648/j.ijbecs.20220804.12
DO  - 10.11648/j.ijbecs.20220804.12
T2  - International Journal of Biomedical Engineering and Clinical Science
JF  - International Journal of Biomedical Engineering and Clinical Science
JO  - International Journal of Biomedical Engineering and Clinical Science
SP  - 48
EP  - 52
PB  - Science Publishing Group
SN  - 2472-1301
UR  - https://doi.org/10.11648/j.ijbecs.20220804.12
AB  - Malaria in pregnancy is associated with many complications therefore the World Health Organization (WHO) in 2012 recommended monthly use of intermittent preventive therapy with sulphadoxine-pyrimethamine (IPTp-SP) to reduce the menace of this disease in malaria endemic region. This study assessed the fetomaternal outcomes of monthly doses of sulphadoxine-pyrimethamine as intermittent preventive treatment (IPTp-SP) in Ibadan. This study was a prospective cohort study. The fetomaternal outcomes of 200 consenting pregnant women on monthly IPTp-SP that completed the study at Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan were analysed. A proforma was used to collect data which included sociodemographic and obstetrics characteristics, prevalence of malaria among the participants and fetomaternal outcomes of the participants. Data obtained were subjected to analysis using statistical package for social sciences (SPSS) for window version 21 and results were presented in appropriate tables, charts and figures. Two hundred participants completed the study and although 11.7% of the participants had malaria parasitaemia at recruitment, only one participant had it at delivery. Most of the participants took 4 doses before delivery. Only 3% of the participants delivered at gestational age less than 34 weeks though 26.5% had preterm delivery. The mean PCV were 30.05±2.60 vs 32.63±3.40 at recruitment and delivery respectively. Only one out of 200 babies and two (1.0%) placental samples tested positive to malaria. The fetal and maternal outcomes of the participants were good following the use of monthly IPTp-SP therefore the uptake of monthly IPTp-SP should be encouraged among pregnant women in malaria endemic area.
VL  - 8
IS  - 4
ER  -

Copy | Download

Author Information

Olaolu Olayinka Oni

Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, Nigeria
Oladapo Olayemi

Department of Obstetrics and Gynaecology, College of Medicine, University of Ibadan, Ibadan, Nigeria
Oluwasomidoyin Bello

Department of Obstetrics and Gynaecology, College of Medicine, University of Ibadan, Ibadan, Nigeria
Olubukola Adesina

Department of Obstetrics and Gynaecology, College of Medicine, University of Ibadan, Ibadan, Nigeria

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Olaolu Olayinka Oni, Oladapo Olayemi, Oluwasomidoyin Bello, Olubukola Adesina. (2022). Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. International Journal of Biomedical Engineering and Clinical Science, 8(4), 48-52. https://doi.org/10.11648/j.ijbecs.20220804.12

Copy | Download

ACS Style

Olaolu Olayinka Oni; Oladapo Olayemi; Oluwasomidoyin Bello; Olubukola Adesina. Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. Int. J. Biomed. Eng. Clin. Sci. 2022, 8(4), 48-52. doi: 10.11648/j.ijbecs.20220804.12

Copy | Download

AMA Style

Olaolu Olayinka Oni, Oladapo Olayemi, Oluwasomidoyin Bello, Olubukola Adesina. Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan. Int J Biomed Eng Clin Sci. 2022;8(4):48-52. doi: 10.11648/j.ijbecs.20220804.12

Copy | Download

@article{10.11648/j.ijbecs.20220804.12,
  author = {Olaolu Olayinka Oni and Oladapo Olayemi and Oluwasomidoyin Bello and Olubukola Adesina},
  title = {Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan},
  journal = {International Journal of Biomedical Engineering and Clinical Science},
  volume = {8},
  number = {4},
  pages = {48-52},
  doi = {10.11648/j.ijbecs.20220804.12},
  url = {https://doi.org/10.11648/j.ijbecs.20220804.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20220804.12},
  abstract = {Malaria in pregnancy is associated with many complications therefore the World Health Organization (WHO) in 2012 recommended monthly use of intermittent preventive therapy with sulphadoxine-pyrimethamine (IPTp-SP) to reduce the menace of this disease in malaria endemic region. This study assessed the fetomaternal outcomes of monthly doses of sulphadoxine-pyrimethamine as intermittent preventive treatment (IPTp-SP) in Ibadan. This study was a prospective cohort study. The fetomaternal outcomes of 200 consenting pregnant women on monthly IPTp-SP that completed the study at Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan were analysed. A proforma was used to collect data which included sociodemographic and obstetrics characteristics, prevalence of malaria among the participants and fetomaternal outcomes of the participants. Data obtained were subjected to analysis using statistical package for social sciences (SPSS) for window version 21 and results were presented in appropriate tables, charts and figures. Two hundred participants completed the study and although 11.7% of the participants had malaria parasitaemia at recruitment, only one participant had it at delivery. Most of the participants took 4 doses before delivery. Only 3% of the participants delivered at gestational age less than 34 weeks though 26.5% had preterm delivery. The mean PCV were 30.05±2.60 vs 32.63±3.40 at recruitment and delivery respectively. Only one out of 200 babies and two (1.0%) placental samples tested positive to malaria. The fetal and maternal outcomes of the participants were good following the use of monthly IPTp-SP therefore the uptake of monthly IPTp-SP should be encouraged among pregnant women in malaria endemic area.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Maternal and Fetal Outcomes of Monthly Ante-Natal Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine in Ibadan
AU  - Olaolu Olayinka Oni
AU  - Oladapo Olayemi
AU  - Oluwasomidoyin Bello
AU  - Olubukola Adesina
Y1  - 2022/11/16
PY  - 2022
N1  - https://doi.org/10.11648/j.ijbecs.20220804.12
DO  - 10.11648/j.ijbecs.20220804.12
T2  - International Journal of Biomedical Engineering and Clinical Science
JF  - International Journal of Biomedical Engineering and Clinical Science
JO  - International Journal of Biomedical Engineering and Clinical Science
SP  - 48
EP  - 52
PB  - Science Publishing Group
SN  - 2472-1301
UR  - https://doi.org/10.11648/j.ijbecs.20220804.12
AB  - Malaria in pregnancy is associated with many complications therefore the World Health Organization (WHO) in 2012 recommended monthly use of intermittent preventive therapy with sulphadoxine-pyrimethamine (IPTp-SP) to reduce the menace of this disease in malaria endemic region. This study assessed the fetomaternal outcomes of monthly doses of sulphadoxine-pyrimethamine as intermittent preventive treatment (IPTp-SP) in Ibadan. This study was a prospective cohort study. The fetomaternal outcomes of 200 consenting pregnant women on monthly IPTp-SP that completed the study at Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan were analysed. A proforma was used to collect data which included sociodemographic and obstetrics characteristics, prevalence of malaria among the participants and fetomaternal outcomes of the participants. Data obtained were subjected to analysis using statistical package for social sciences (SPSS) for window version 21 and results were presented in appropriate tables, charts and figures. Two hundred participants completed the study and although 11.7% of the participants had malaria parasitaemia at recruitment, only one participant had it at delivery. Most of the participants took 4 doses before delivery. Only 3% of the participants delivered at gestational age less than 34 weeks though 26.5% had preterm delivery. The mean PCV were 30.05±2.60 vs 32.63±3.40 at recruitment and delivery respectively. Only one out of 200 babies and two (1.0%) placental samples tested positive to malaria. The fetal and maternal outcomes of the participants were good following the use of monthly IPTp-SP therefore the uptake of monthly IPTp-SP should be encouraged among pregnant women in malaria endemic area.
VL  - 8
IS  - 4
ER  -

Copy | Download